Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer identifier:
NCT04592237 (

Treatment in people with aggressive metastatic prostate cancer

Study Contact Information:

For additional information, please contact:

Ana Aparicio  by phone: 713-563-6969 or by email: [email protected]    

About the Study

This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.

Type of Study

This is a two-arm, randomized, open-label study.

What the Study Involves

Induction phase

Maintenance phase

Study participants will be followed up to 5 years.

Study Site

This Study is Open To:

Men age 18 years or older who meet the following criteria:

Check for additional eligibility. 

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.